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Abstract
Introduction: The impact of a vascular complication (VC) in the setting of intraaortic
balloon pump (IABP) supported PCI on clinical outcomes is unclear.
Methods: Using data from the BCIS National PCI Database, multivariate logistic
regression was used to identify independent predictors of a VC. Propensity scoring
was used to quantify the association between a VC and outcomes.
Results: Between 2007 and 2014, 9,970 PCIs in England and Wales were supported by
IABP (1.6% of total PCI), with 224 femoral VCs (2.3%). Annualized rates of a VC reduced
as the use of radial access for PCI increased. The independent predictors of a VC
included a procedural complication (odds ratio [OR] 2.9, p < .001), female sex (OR 2.3,
p < .001), PCI for stable angina (OR 3.47, p = .028), and use of a glycoprotein inhibitor
(OR 1.46 [1.1:2.5], p = .04), with a lower likelihood of a VC when radial access was used
for PCI (OR 0.48, p = .008). A VC was associated with a higher likelihood of transfusion
(OR 5.7 [3.5:9.2], p < .0001), acute kidney injury (OR 2.6 [1.2:6.1], p = .027), and peri-
procedural MI (OR 3.2 [1.5:6.7], p = .002) but not with adjusted mortality at discharge
(OR 1.2 [0.8:1.7], p = .394) or 12-months (OR 1.1 [0.76:1.56], p = .639). In sensitivity
analyses, there was a trend towards higher mortality in patients experiencing a VC who
underwent PCI for stable angina (OR 4.1 [1.0:16.4], p value for interaction .069).
Discussion and Conclusions
Although in-hospital morbidity was observed to be adversely affected by occurrence
of a VC during IABP-supported PCI, in-hospital and 1-year survival were similar
between groups.
Abbreviations: BCIS, British Cardiovascular Intervention Society; CABG, coronary artery bypass surgery; FA, femoral access; IABP, intraaortic balloon pump; IVUS, intravascular ultrasound; LAD,
left anterior descending; LMS, left main stem; MACCE, major adverse cardiac or cerebrovascular events; MI, myocardial infarction; NYHA, New York Heart Association; PCI, percutaneous
coronary intervention; uLMS-PCI, unprotected left main stem percutaneous intervention.
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1 | INTRODUCTION
The evolution of revascularization for coronary artery disease has
resulted in percutaneous coronary intervention (PCI) becoming more
complex in contemporary practice with advancing patient age necessitat-
ing increasingly the utilization of calcium modification strategies.1 Despite
recent controversies regarding the Everolimus-Eluting Stents or Bypass
Surgery for Left Main Coronary Artery Disease (EXCEL) trial, PCI for left
main disease also continues to represent an increasingly large percentage
of the total PCI procedures undertaken.2,3 Furthermore, in parallel with
increasing patient age and the uptake of transaortic valve replacement
(TAVR), severe concomitant valve disease is also more prevalent.4 With
increasing patient and procedural complexity comes an increased likeli-
hood of potential complications such as coronary perforation, persistent
no reflow, and arrhythmias leading to hemodynamic instability.5
As a result of the well-documented increase in procedural complex-
ity, interest has arisen in the use of left ventricular support devices as
an adjunct to PCI. Although intraaortic balloon pumps are historically
the dominant LV support device, recent interest has focused on the
Impella device and the significant augmentation of cardiac output that
it provides.6,7 However, two recent studies have identified significant
bleeding and vascular risks associated with Impella use.8,9 Furthermore,
although the significant hemodynamic support provided by the Impella
remains attractive, their prohibitive cost in many healthcare systems
means that IABP remains the dominant device used. Although historical
studies of most patient subsets undergoing PCI have identified vascular
complications as correlating closely with adverse short-term and
medium-term outcomes, little is known about the temporal changes in
vascular complications and bleeding associated with IABP use, and the
subsequent impact such as complication has on medium term sur-
vival.10-13 One unexplored hypothesis is that the morbidity associated
with such LV support devices might offset any benefit gained from
improved hemodynamics.
Therefore, the aims of the present study were to use the British
Coronary Intervention Society (BCIS) National PCI Database to study
the temporal changes in vascular complications occurring during
IABP-supported PCI, examine the independent predictors of vascular
complications, and to assess the impact of a vascular complication on
12-month survival.
2 | METHODS
2.1 | Study design and participants
We analyzed data from all patients undergoing PCI in England and
Wales between January 1, 2007 and December 31, 2014. The study
patient flow is illustrated in Figure S1 with the study cohort consisting
of all patients who underwent PCI for any indication with IABP sup-
port. Participants with missing information on vascular complication
status were excluded from the study. The final study population of
9,790 procedures was then classified as to whether a vascular compli-
cation had occurred or not.
2.2 | Study setting and sources of data
The BCIS maintains data prospectively on PCI procedures throughout
United Kingdom, a process overseen by the National Institute of Car-
diovascular Outcomes Research (NICOR). Entry of all PCI procedures
by UK interventional operators is mandated as part of their profes-
sional revalidation. The governance and quality of these data have
previously been validated and published.14,15 In 2014, approximately
98% of all PCI procedures performed in the National Health Service
(NHS) hospital in England and Wales were recorded on this National
database (www.bcis.org.uk/). The BCIS database consists of over
120 clinical, demographical, procedural, and outcomes variables with
approximately 80,000 new entries uploaded each year.15,16 BCIS
records are linked with Office of National Statistics (ONS) data for
postdischarge mortality tracking in all patients from England and Wales
by using their unique National Health Service (NHS) numbers. Patients
from Scotland and Northern Ireland were not included in this study
due to the absence of the ONS-linked postdischarge mortality data.
2.3 | Study definitions
The BCIS National PCI Audit records use of an intraaortic balloon
pump during PCI although does not record whether use is in a
planned fashion or consequent to hemodynamic collapse during the
procedure. Study definitions were used as in the BCIS National PCI
Audit (available at https://www.bcis.org.uk/resources/bcis-ccad-
database-resources/datasets-history/). For the purposes of the study,
a vascular complication was defined as an arterial dissection, arterial
occlusion, retroperitoneal hemorrhage, any complication requiring sur-
gical intervention, a false aneurysm (with conservative, surgical,
thrombin injection, or compressive management separately recorded),
or arterial hemorrhage with delayed discharge. In the BCIS database,
to fulfill the cardiogenic shock criteria, patients must have both sys-
temic hypotension (systolic BP of ≤90 mmHg) and evidence of periph-
eral hypoperfusion such as a weak pulse, pallor, cool peripheries, or
diaphoresis. Pre-PCI or post-PCI disease severity was defined as ves-
sels with a stenosis ≥70% in the case of the LAD, circumflex or right
coronary arteries, or ≥50% in the case of the left main artery. Chronic
renal failure was defined as chronic dialysis, history of renal transplant,
or a creatinine >200 μmol/L. An acute coronary complication was
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defined as a coronary perforation, coronary/aortic dissection, major
side branch loss, severe no/slow flow, or shock induced by the proce-
dure. In-hospital major adverse cardiac or cerebrovascular events
(MACCE) were defined as a combination of death, stroke, or myocar-
dial infarction after PCI.
2.4 | Data analyses
Trends for the use of IABP, access site and VC over time were con-
structed and significance was examined using linear regression. We
examined the baseline and procedural characteristics of patients by
vascular complication status. We tested for associations between
each categorical variable and coronary perforation using a Chi-
squared test, and for continuous variables we used one-way analysis
of variance. We then performed separate multivariate analyses of the
predictors of a vascular complication using multivariate logistic regres-
sion to investigate the influence of variables that have the potential
for being included in the linear component of a proportional hazard
model. We first imputed missing data on baseline covariate using mul-
tiple imputations with chained equation (missing data points are pres-
ented in Table S1). We selected a final model for each outcome by
using forward stepwise variable selection and an inclusion criterion of
p < .1. Variables included in this analysis were age, sex, clinical presen-
tation, emergency indication, cardiogenic shock, angina score, dyspnea
score, recent thrombolysis, previous MI, previous CABG, previous
PCI, diabetes, body mass index, ejection fraction (EF), baseline disease
severity, left main stem intervention, number of stents used, glycopro-
tein inhibitor use, rotational atherectomy, embolic protection, use of
inotropes, closure device, history of smoking, hypertension, previous
stroke, peripheral vascular disease, severe valve disease, ventilated
preprocedure, Q wave on ECG, chronic renal failure, and radial use.
We also included the occurrence of an acute coronary complication in
this modeling (rather than as an outcome event), as it seemed more
likely that an IABP was used as a result of an acute coronary complica-
tion, that is, that the reverse scenario was rather unlikely.
We then explored the association between a VC and clinical out-
comes. We initially calculated the crude rates by VC status. Then
using a Cox proportional hazard mode, we estimated the
corresponding hazard ratio. To adjust for baseline imbalances, we
performed a propensity score analysis in order to balance for impor-
tant covariates that might bias estimates for causal inferences. The
following variables were used in the propensity score analysis: age,
sex, clinical presentation, emergency indication, cardiogenic shock,
previous MI, previous CABG, previous PCI, diabetes, EF, baseline dis-
ease severity, left main stem intervention, use of intracoronary imag-
ing, glycoprotein inhibitor use, rotational atherectomy, use of
inotropes, use of cardiopulmonary support, hypertension, previous
stroke, peripheral vascular disease, severe valve disease, ventilated
preprocedure, Q wave on ECG, and chronic renal failure. As above,
we also adjusted outcomes for the occurrence any acute coronary
procedural coronary complication. The propensity scores for each
patient was derived using the inverse probability of treatment weight
(IPTW). More precisely, one estimates the probability that a particu-
lar patient is assigned to one of the two groups as a function of that
individual's covariates (the propensity score). Each individual obser-
vation was then given a weight equal to the inverse of this propen-
sity score to create two pseudo-populations of exposed and
unexposed patients who now represent what would have happened
to the entire population under those two “treatment” conditions.
The advantage of this method is that it is inclusive as it uses all
patients in a study; therefore, no loss of sample occurs as in other
conditioning methods such as matching or stratification. We also
normalized the weights by dividing them by the mean weight. Those
weights were then used to derive weighted hazard ratios. A sensitiv-
ity analysis examining the effect of a VC by access site (radial
vs. femoral) was also undertaken. Subgroup analyses for gender, age
>75, shock, stable angina, EF <30, acute coronary complication and
left main PCI were also performed. Finally, an outcome analysis
including only patients with hemorrhage, that is, with exclusion of
patients with a vascular complication but without hemorrhage, was
also undertaken.
F IGURE 1 Left: Annual rate
of IABP use to support PCI in
England and Wales 2007–2014,
p = .325 for trend; Right: Number
of indications for IABP use
KINNAIRD ET AL. 3
3 | RESULTS
3.1 | Temporal changes in IABP use and vascular
complications between 2007 and 2014
Between 2007 and 2014, there were 9,970 IABP-supported PCI pro-
cedures undertaken (1.6% of total PCI) with no significant trend in the
frequency of IABP use (Figure 1, left panel). The most frequent indica-
tions for IABP use were cardiogenic shock (54.8%), multivessel coro-
nary artery disease (27.6%), EF less than 30% (23.4%), left main PCI
(19.8%), acute procedural complication (19.1%) and PCI to the last
remaining vessel (5.1%). The mean number of indications for IABP use
was 1.87 ± 0.97 with many patients having multiple reasons for IABP
use (Figure 1, right panel). In total, there were 224 vascular complica-
tions (2.3%) with major arterial hemorrhage, femoral artery aneurysm,
and femoral artery dissection the most common events. There was a
significant reduction in the annualized rates of a VC from 4.1% in
2007 to 1.4% in 2014 (p < .001 for trend) which mirrored a significant
increase in radial approach over the same period was observed
(14.3–43.9%, p < .001 for trend, Figure 2 left and center panel). When
analyzed by access site for PCI, annualized rates of a VC were consis-
tently lower when radial access was used, although the annualized VC
rates dropped significantly in both access groups (Figure 2 right
panel).
3.2 | Baseline demographics, and procedural data
by vascular complication status during IABP-
supported PCI between 2007 and 2014
In general, there were few baseline characteristics associated with a
vascular complication. Only female sex, previous CABG, stable angina
indication, clopidogrel use, and baseline disease severity were
observed to be associated with a greater frequency of a vascular com-
plication (Table 1). However procedural characteristics differed
between the two cohorts with no. vessels/lesions attempted, glyco-
protein inhibitor use, radial access for PCI, left main PCI, size and
number of stents used, and the occurrence of an acute coronary com-
plication all observed to be associated with a significant increase in
vascular complications (Table 2). In multivariate analysis of the inde-
pendent predictors of a vascular complication, an acute coronary com-
plication (OR 2.86, 95% confidence interval 1.94–4.22, p < .001),
female sex (OR 2.03, 95% confidence interval 1.38–3.00, p < .001),
stable angina indication (OR 3.47, 95% confidence interval
1.14–10.40, p ≤ .028) and glycoprotein inhibitor use (OR 1.46, 95%
confidence interval 1.00–2.19, p = .050) were associated with a
greater likelihood of a vascular complication, whilst diabetes mellitus
(OR 0.60, 95% confidence interval 0.36–0.99, p = .046) and use of the
radial artery for PCI (OR 0.48, 95% confidence interval 0.28–0.83,
p = .008) were associated with a lower likelihood (Table 3). Use of a
closure device, patient age, body mass index, or a history of peripheral
vascular disease were not associated with a differing risk of a vascular
complication.
3.3 | Clinical outcomes by vascular complication
status during IABP-supported PCI between 2007
and 2014
Clinical outcomes for the whole IABP-supported PCI cohort was poor
with an observed in-hospital mortality of 28.4% and a 12-month mor-
tality of 41.0%. For those who survived, median LOS was 5 days (IQR
2–10 days). In unadjusted analysis, although transfusion (19.8
vs. 2.7%, p < .001), periprocedural CVA (2.4 vs. 0.6% p = .011),
F IGURE 2 Left panel: Annual rate of vascular complications during IABP use to support PCI in England and Wales 2007–2014 (p < .001 for
trend); Middle panel: Temporal change in the access site for PCI used during IABP supported PCI (p < .001 for trend); Right panel: Annual rate of
vascular complications by access site during IABP use to support PCI in England and Wales 2007–2014
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periprocedural MI (6.1 vs. 1.6%, p < .001), and acute kidney injury (4.7
vs. 1.5%, p < .001) were more likely when a VC occurred, in-hospital
death, MACCE and 12-month mortality were similar between both
groups (Table 4). There was a trend for median length of stay to be
longer when a VC occurred although this difference did not reach sta-
tistical significance. In adjusted analysis, a vascular complication dur-
ing IABP-supported PCI was associated with an increase in blood
transfusion (OR 5.72, [3.54:9.23], p < .001), periprocedural MI (OR
1.58, [1.51:6.73], p = .002), and acute kidney injury (OR 2.60,
[1.11:6.11], p = .027) but not increased in-hospital (OR 1.17,
[0.81:1.70], p = .394) or 12-month mortality (OR 1.09, [0.76:1.58],
p = .639) (Table 5). Adjusted Kaplan Meier curves by vascular compli-
cation status are presented in Figure 3. When the outcome analysis
was restricted to patients with major hemorrhage, that is, with exclu-
sion of patients with a vascular complication but without hemorrhage,
the findings were similar to the whole cohort with an excess of trans-
fusion (OR 6.41, [3.12:13.1], p < .001) and periprocedural MI (OR
4.27, [1.52:11.96], p = .006) but similar survival at 12-months follow-
up (OR 1.20, [0.65:2.21], p = .554) (Table S2). In sensitivity analyses, in
the radial sub-group, patient outcomes were similar to the overall
group with no difference in 12-month survival observed between
patients with or without a vascular complication (OR for 12-month
mortality 0.84 [0.43–1.92], p = .601). Although the 12-month mortal-
ity for several subgroups including female sex, age >75 years, EF
>30% and left main PCI did not differ from the overall study findings,
there was a trend for a vascular complication in the setting of stable
angina PCI to be associated with increased 12-month mortality (OR
4.07, [1.01:16.39], p = .048, p value for interaction = .069) (Figure 4).
4 | DISCUSSION
The findings of the current study can be summarized as follows:
(a) Vascular complications occurred in 2.3% of all IABP-supported PCI;
(b) There was a significant reduction in the annualized rates of a VC
which mirrored a significant increase in radial artery access for PCI in
the same period; (c) The independent predictors of an increase in VC
were a procedural complication, female sex, PCI for stable angina, and
use of a glycoprotein inhibitor, whilst a lower likelihood of a VC
occurred when radial access was used; (d) Although a VC was associ-
ated with a higher likelihood of transfusion, acute kidney injury, and
periprocedural MI, its occurrence was not associated with a higher
rate of in-hospital or 12-month mortality; (e) In sensitivity analyses,
there was a trend toward higher mortality in patients who sustained a
vascular complication during ABP-supported PCI for stable angina.
The observed frequency of vascular complications complicating
IABP-supported PCI varies widely in the literature. In a meta-analysis
of 20 studies, the overall rate of vascular complications varied
TABLE 1 Baseline characteristics by vascular complication status after IABP-supported PCI performed in England and Wales between 2007
and 2014
Variable No vascular complication (n = 9,566) Vascular complication (n = 224) p-value
Age (years) ± SD 67.7 ± 12.3 67.9 ± 11.9 .390
Female sex, no. (%) 2,621 (27.5) 82 (37.6) <.001
BMI (kg/m2) ± SD 27.1 ± 5.0 27.3 ± 5.2 .422
History of hypertension, no. (%) 4,494 (50.8) 116 (56.3) .134
Diabetes mellitus, no. (%) 2,053 (22.9) 45 (21.3) .657
History of smoking, no. (%) 4,915 (62.4) 115 (59.5) .466
Previous MI, no. (%) 2,459 (28.3) 55 (27.1) .746
Previous stroke, no. (%) 538 (6.1) 17 (8.3) .255
Peripheral vascular disease, no. (%) 767 (8.7) 12 (5.8) .189
Chronic renal disease, no. (%) 641 (7.4) 18 (8.7) .597
Previous PCI, no. (%) 1,373 (15.0) 25 (11.7) .207
Previous CABG, no. (%) 645 (7.0) 26 (12.2) .007
EF (%), ±SD 34.3 ± 14.0 35.2 ± 15.5 .244
EF <30%, no. (%) 2,300 (45.9) 61 (46.9) .894
Recent thrombolysis, no. (%) 573 (6.7) 13 (6.6) .999
Stable angina indication, no. (%) 478 (4.9) 18 (8.2) .046
Clopidogrel use, no. (%) 5,797 (70.2) 165 (82.5) <.001
Out of hospital cardiac arrest, no. (%) 186 (19.9) 3 (23.1) .775
Cardiogenic shock on presentation, no. (%) 5,364 (56.8) 102 (47.0) .004
Ventilated preprocedure, no. (%) 2,224 (25.0) 31 (14.9) .001
Mean NYHA class, ±SD 2.36 ± 1.62 2.01 ± 1.57 .020
No. vessels diseased ±SD 1.93 ± 1.00 2.11 ± 1.04 .005
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between 0.94 and 31.1% in published studies a finding driven in part
by differing clinical scenarios, variable study sizes, and the inclusion of
historical studies with outdated practice.16 In the first randomized trial
of IABP to support primary PCI, the Second Primary Angioplasty in
Myocardial Infarction (PAMI-II) Trial investigators observed major
bleeding and/or vascular complications in over 20% of patients in the
IABP arm.17 In a more contemporary study, the IABP-SHOCK II trial
investigators observed severe bleeding occurred in 3.3%, and periph-
eral ischemic complications in 4.4% of the IABP arm. Therefore, in the
present study the vascular complication rate was lower than
previously reported, albeit with a significant temporal reduction in its
observed frequency.18-20
Use of both Impella and IABP to support PCI remains controversial
given the lack of robust randomized data confirming improving patient
outcomes when used. In the IABP-SHOCK II trial, 12-month survival
was similar between IABP and control arms.18-20 Similarly, in the Bal-
loon Pump-Assisted Coronary Intervention Study trial, survival at
6-months was not statistically different between the two arms.21 In an
attempt to improve patient outcomes, the pivotal PROTECT II trial ran-
domized patients undergoing complex PCI to support with Impella or
TABLE 2 Procedural variables by vascular complication status after IABP-supported PCI performed in England and Wales between 2007
and 2014
Variable No vascular complication (n = 9,566) Vascular complication (n = 224) p-value
On-site surgical cover, no. (%) 6,191 (70.0) 147 (70.2) .988
No. vessels attempted ±SD 1.47 ± 0.74 1.63 ± 0.81 .001
No. lesions attempted ±SD 1.64 ± 0.91 1.80 ± 1.09 .004
No. chronic total occlusions attempted, no. (%) 885 (9.9) 30 (14.5) .037
Radial access for PCI, no. (%) 3,032 (32.6) 50 (23.0) .028
Closure device, no. (%) 1,908 (23.7) 46 (24.6) .831
Glycoprotein inhibitor, no. (%) 4,725 (51.9) 130 (60.5) .016
Intra-coronary imaging, no. (%) 677 (8.1) 14 (7.1) .719
Vessel attempted, no. (%)
Left main 1,943 (20.4) 67 (30.7) <.001
Left anterior descending 5,456 (57.4) 126 (57.8) .979
Circumflex 2,643 (27.8) 71 (32.6) .144
Right 2,937 (30.9) 67 (30.7) .949
Graft 293 (3.1) 10 (4.6) .231
Left main protected, no. (%) 244 (3.4) 11 (7.4) .015
Aspiration thrombectomy, no. (%) 3,090 (33.6) 70 (32.9) .892
Rotational atherectomy, no. (%) 284 (3.7) 11 (5.6) .216
Inotrope use, no. (%) 2,360 (24.6) 55 (25.1) .937
Largest stent (mm) ±SD 3.40 ± 0.66 3.54 ± 0.75 .001
Longest stent (mm) ±SD 27.7 ± 16.6 27.3 ± 14.3 .371
No. stents used ±SD 1.77 ± 1.35 2.10 ± 1.61 <.001
Acute procedural complication, no. (%) 1,866 (20.9) 90 (43.9) <.001
No. successful lesions ±SD 1.46 ± 0.94 1.53 ± 1.17 .126
TABLE 3 Significant associations between covariates and a vascular complication status after IABP-supported PCI performed in England and
Wales between 2007 and 2014
Variable
OR for vascular complication
vs. no vascular complication [95% CI] p-value
Procedural complication 2.86 [1.94:4.22] <.001
Female sex 2.03 [1.38:3.00] <.001
Stable angina 3.47 [1.14:10.4] .028
Glycoprotein inhibitor 1.46 [1.00:2.19] .050
Diabetes mellitus 0.60 [0.36:0.99] .046
Radial access for PCI 0.48 [0.28:0.83] .008
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IABP, with no statistical difference observed between the two arms.22
The controversy of LV support during PCI has deepened further with
two recent registries identifying adverse outcomes in patients receiving
Impella augmentation.8,9 One hypothesis underpinning these observa-
tions is that the morbidity associated with such LV support devices
might offset any benefit gained from improved hemodynamics.
Therefore, a major strength of the current study, aside with the
number of procedures included and the longitudinal data entry all-
owing study of temporal trends, is that it is the first study of a national
registry investigating whether vascular complications associated with
IABP use independently predict adverse in-hospital and 12-month sur-
vival. The observation that vascular complications were associated
with increased periprocedural MI and acute kidney injury might be
explained by their adverse hemodynamic consequences, the deleteri-
ous effects of a transfusion, and complications arising from reparative
interventions and imaging.23 However, the lack of a mortality signal
associated with a vascular complication in the overall cohort is at odds
with most other studies where major bleeding and/or a vascular
complication were strongly predictive of higher short-term and
medium-term mortality.24,25 The likely explanation for this lack of an
association is that the life-threatening pathology underpinning the
need for IABP support overwhelms any adverse consequences of a
vascular complication. One caveat to these observations is that the
reported rates of vascular complications were relatively low and, there-
fore, the total event rates were relatively small. Nevertheless, given
TABLE 4 Unadjusted outcomes by vascular complication status after IABP supported PCI performed in England and Wales between 2007
and 2014
Variable No vascular complication (n = 9,566) Vascular complication (n = 224) p-value
Transfusion, no. (%) 242 (2.7) 42 (19.8) <.001
Gastrointestinal bleed, no. (%) 90 (0.9) 4 (1.8) .351
Periprocedural CVA, no. (%) 59 (0.6) 5 (2.4) .011
Periprocedural MI, no. (%) 148 (1.6) 13 (6.1) <.001
Acute kidney injury, no. (%) 140 (1.5) 10 (4.7) <.001
Emergency CABG, no. (%) 123 (1.4) 7 (3.3) .038
Median length of hospital stay, (IQR) 5 (2–10) 6 (2–12) .083
In-hospital death, no. (%) 2,667 (28.4) 62 (28.7) .998
In-hospital MACCE, no. (%) 2,813 (29.6) 74 (34.1) .170
Mortality at 12-months, no. (%) 3,231 (41.1) 71 (36.7) .259
TABLE 5 Adjusted clinical outcomes by vascular complication status after IABP supported PCI performed in England and Wales between
2007 and 2014
Variable
OR for vascular complication
vs. no vascular complication [95% CI] p-value
Transfusion 5.72 [3.54:9.23] <.001
Gastrointestinal bleed 0.82 [0.15:4.50] .822
Periprocedural CVA 1.58 [0.31:8.01] .580
Periprocedural MI 3.19 [1.51:6.73] .002
Acute kidney injury 2.60 [1.11:6.11] .027
Emergency CABG 1.40 [0.40:4.92] .597
In-hospital death 1.17 [0.81:1.70] .394
In-hospital MACCE 1.37 [0.96:1.96] .078
Mortality at 12-months 1.09 [0.76:1.58] .639
F IGURE 3 Mortality by vascular complication status during IABP-
supported PCI in England and Wales 2007–2014 [Color figure can be
viewed at wileyonlinelibrary.com]
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the overall high MACCE and mortality, and the narrow odds ratios, it
seems unlikely that a type II error is present.
Notwithstanding the lack of a robust survival advantage offered
by IABP to support PCI, it is reassuring that in the acute setting at
least, there is no mortality cost of a vascular complication. However, it
is noteworthy that in the stable angina setting, there was a strong
trend for excess mortality when a vascular complication occurs. This
observation combined with the temporal signal for vascular complica-
tions to occur less frequently when the radial artery was used for PCI,
supports the concept that radial access should be used for PCI when-
ever possible even when a single femoral artery puncture is still
required for LV support. These observations are in keeping with the
Radial versus femoral approach comparison in percutaneous coronary
intervention with intraaortic balloon pump support (RADIAL PUMP
UP) registry in which high-risk patients undergoing PCI and requiring
IABP support appeared to have fewer adverse events if transradial
access was used for PCI instead of transfemoral access.26 Although
small case series have reported successful introduction of IABP to
support patients using brachial or subclavian access, whether this
results in improved patient outcomes versus femoral access is uncer-
tain in the absence of randomized trial data.27,28
5 | LIMITATIONS
As with any registry, these data are observational, subject to
unmeasured confounders and therefore cannot be used to imply causal-
ity. Additionally, the timing of IABP insertion not recorded and whether
its use was up-front or as bail-out. The duration of IABP use is also not
recorded, a factor which has been correlated with complications in pre-
vious studies. As data is self-reported, clinical events may be under-
reported. We have made assumptions that under-reporting is randomly
distributed but it remains a possibility that nonrandom under-reporting
is an unmeasured confounder. Finally, limb or gut ischemia are not
recorded in the BCIS database although any surgical repair is, and there-
fore the effect of this complication in outcomes cannot be assessed.
6 | CONCLUSIONS
Vascular complications associated with IABP use have declined in fre-
quency as radial access use for PCI increased. Although increases in sev-
eral in-hospital nonfatal outcomes were observed with the occurrence of
a vascular complication, in-hospital and 1-year survival was not affected.
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